Methods of treating inflammatory disorders using high concentration natalizumab compositions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
C07K-016/28
출원번호
US-0530879
(2012-06-22)
등록번호
US-9533044
(2017-01-03)
발명자
/ 주소
Maloney, Kevin
출원인 / 주소
BIOGEN MA INC.
대리인 / 주소
Lando & Anastasi, LLP
인용정보
피인용 횟수 :
0인용 특허 :
32
초록
Formulations of VLA-4 binding antibody are described.
대표청구항▼
1. A method of treatment of a patient with an inflammatory disorder, the method comprising subcutaneously or intramuscularly administering a dose of 0.25 to 1.5 mL of a stable aqueous composition comprising 150 mg/mL natalizumab, 10 mM sodium phosphate buffer, 140 mM sodium chloride, and 0.04% (w/v)
1. A method of treatment of a patient with an inflammatory disorder, the method comprising subcutaneously or intramuscularly administering a dose of 0.25 to 1.5 mL of a stable aqueous composition comprising 150 mg/mL natalizumab, 10 mM sodium phosphate buffer, 140 mM sodium chloride, and 0.04% (w/v) polysorbate 80, at pH 5.5-6.5. 2. The method of claim 1, wherein the composition has a viscosity of 5-30 cP at ambient temperature. 3. The method of claim 1, wherein the composition is stable for at least 12 months at a temperature of about 2° C. to about 8° C. 4. The method of claim 1, wherein the composition is stable for at least 24 months at a temperature of about 2° C. to about 8° C. 5. The method of claim 1, wherein the composition shows less than 10% aggregation following storage for at least 12 months at a temperature of about 2° C. to about 8° C. 6. The method of claim 1, wherein the composition shows less than 10% aggregation following storage for 18 months at a temperature of about 2° C. to about 8° C. 7. The method of claim 1, wherein the method comprises administering 1 mL of the composition. 8. The method of claim 1, wherein the inflammatory disorder is multiple sclerosis. 9. The method of claim 1, wherein the composition is administered subcutaneously. 10. The method of claim 1, wherein the composition comprises sodium phosphate monobasic, monohydrate or sodium phosphate dibasic heptahydrate or both. 11. The method of claim 1, wherein the composition retains its biological activity after storage of the composition for at least 12 months at a temperature of about 2° C. to about 8° C. 12. The method of claim 1, wherein the composition has a potency of at least 97% at 25° C. after storage for 12 months at a temperature of 5° C. 13. The method of claim 1, wherein the inflammatory disorder is asthma. 14. The method of claim 1, wherein the inflammatory disorder is an arthritic disorder. 15. The method of claim 1, wherein the inflammatory disorder is diabetes. 16. The method of claim 1, wherein the inflammatory disorder is a fibrotic disorder. 17. The method of claim 1, wherein the inflammatory disorder is an inflammatory bowel disease. 18. The method of claim 1, wherein the method comprises subcutaneously or intramuscularly administering two doses of 1 mL of the composition. 19. A method of treatment of a patient with an inflammatory disorder, the method comprising subcutaneously or intramuscularly administering a dose of 0.25 to 1.5 mL of a stable aqueous composition consisting essentially of 150 mg/mL natalizumab, 10 mM sodium phosphate buffer, 140 mM sodium chloride, and 0.04% (w/v) polysorbate 80, at pH 5.5-6.5. 20. The method of claim 19, wherein the composition has a viscosity of 5-30 cP at ambient temperature. 21. The method of claim 19, wherein the composition is stable for at least 12 months at a temperature of about 2° C. to about 8° C. 22. The method of claim 19, wherein the composition is stable for at least 24 months at a temperature of about 2° C. to about 8° C. 23. The method of claim 19, wherein the composition shows less than 10% aggregation following storage for at least 12 months at a temperature of about 2° C. to about 8° C. 24. The method of claim 19, wherein the composition shows less than 10% aggregation following storage for 18 months at a temperature of about 2° C. to about 8° C. 25. The method of claim 19, wherein the method comprises administering 1 mL of the composition. 26. The method of claim 19, wherein the inflammatory disorder is multiple sclerosis. 27. The method of claim 19, wherein the composition retains its biological activity after storage of the composition for at least 12 months at a temperature of about 2° C. to about 8° C. 28. The method of claim 19, wherein the composition has a potency of at least 97% at 25° C. after storage for 12 months at a temperature of 5° C. 29. The method of claim 19, wherein the inflammatory disorder is an inflammatory bowel disease. 30. The method of claim 19, wherein the method comprises subcutaneously or intramuscularly administering two doses of 1 mL of the composition. 31. A method of treatment of a patient with an inflammatory disorder, the method comprising subcutaneously or intramuscularly administering a dose of 0.25 to 1.5 mL of a stable aqueous composition consisting of 150 mg/mL natalizumab, 10 mM sodium phosphate buffer, 140 mM sodium chloride, and 0.04% (w/v) polysorbate 80, at pH 5.5-6.5. 32. The method of claim 31, wherein the composition has a viscosity of 5-30 cP at ambient temperature. 33. The method of claim 31, wherein the composition is stable for at least 12 months at a temperature of about 2° C. to about 8° C. 34. The method of claim 31, wherein the composition is stable for at least 24 months at a temperature of about 2° C. to about 8° C. 35. The method of claim 31, wherein the composition shows less than 10% aggregation following storage for at least 12 months at a temperature of about 2° C. to about 8° C. 36. The method of claim 31, wherein the composition shows less than 10% aggregation following storage for 18 months at a temperature of about 2° C. to about 8° C. 37. The method of claim 31, wherein the method comprises administering 1 mL of the composition. 38. The method of claim 31, wherein the inflammatory disorder is multiple sclerosis. 39. The method of claim 31, wherein the composition retains its biological activity after storage of the composition for at least 12 months at a temperature of about 2° C. to about 8° C. 40. The method of claim 31, wherein the composition has a potency of at least 97% at 25° C. after storage for 12 months at a temperature of 5° C. 41. The method of claim 31, wherein the inflammatory disorder is an inflammatory bowel disease. 42. The method of claim 31, wherein the method comprises subcutaneously or intramuscularly administering two doses of 1 mL of the composition. 43. A method of treatment of a patient with multiple sclerosis, the method comprising subcutaneously or intramuscularly administering a dose of 0.25 to 1.5 mL of an aqueous composition comprising 150 mg/mL natalizumab, 10 mM sodium phosphate buffer, 140 mM sodium chloride, and 0.04% (w/v) polysorbate 80, at pH 5.5-6.5, wherein the composition has a viscosity of 5-30 cP at ambient temperature and shows less than 10% aggregation after storage for at least 12 months at a temperature of about 2° C. to about 8° C. 44. The method of claim 43, wherein the method comprises subcutaneously or intramuscularly administering two doses of 1 mL of the composition.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (32)
Hutchinson Francis G. (Lymm GBX), Continuous release pharmaceutical compositions.
Salfeld Jochen G. ; Allen Deborah J.,GBX ; Hoogenboom Hendricus R. J. M. ; Kaymakcalan Zehra ; Labkovsky Boris ; Mankovich John A. ; McGuinness Brian T.,GBX ; Roberts Andrew J.,GBX ; Sakorafas Paul ;, Human antibodies that bind human TNF.alpha..
Bendig Mary M.,GBX ; Leger Olivier J.,GBX ; Saldanha Jose,GBX ; Jones S. Tarran,GBX ; Yednock Ted A., Humanized antibodies against leukocyte adhesion molecule VLA-4.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Burke, David J.; Buckley, Shaun E.; Lehrman, Sherwood Russ; O'Connor, Barbara Horsey; Callaway, James; Phillips, Christopher P., Immunoglobulin formulation and method of preparation thereof.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Burke, David J.; Buckley, Shaun E.; Lehrman, Sherwood Russ; O'Connor, Barbara Horsey; Callaway, James; Phillips, Christopher P., Method for treating multiple sclerosis and crohn's disease.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Queen Cary L. (Los Altos CA) Schneider William P. (Mountain View CA) Selick Harold E. (Belmont CA), Polynucleotides encoding improved humanized immunoglobulins.
Bornkamm Georg Wilhelm,DEX ; Eick Dirk,DEX ; Kempkes Bettina ; Jochner Nicola Maria,DEX ; Strobl Lothar J.,DEX, Process for the preparation of human monoclonal antibodies and their use.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.